Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Updates FY 2026 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 1.200-1.346 for the period, compared to the consensus EPS estimate of 1.250. The company issued revenue guidance of $52.1 billion-$54.5 billion, compared to the consensus revenue estimate of $52.1 billion.

Bayer Aktiengesellschaft Stock Up 2.8%

BAYRY stock traded up $0.39 during midday trading on Tuesday, hitting $13.96. The stock had a trading volume of 420,810 shares, compared to its average volume of 1,251,173. Bayer Aktiengesellschaft has a 52-week low of $7.19 and a 52-week high of $15.23. The firm has a market cap of $54.84 billion, a price-to-earnings ratio of -21.80, a price-to-earnings-growth ratio of 4.46 and a beta of 0.55. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.05 and a quick ratio of 0.70. The business has a 50-day moving average of $12.36 and a two-hundred day moving average of $12.08.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.06. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, equities research analysts forecast that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on BAYRY shares. Jefferies Financial Group upgraded Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. Deutsche Bank Aktiengesellschaft upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Thursday, July 2nd. DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Finally, Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.